Education
About Us
Working with TipRanks
Follow Us
Brainstorm Cell Therapeutics (BCLI)
:BCLI
BCLI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.52 - $3.78
Previous CloseN/A
Volume34.73K
Average Volume (3M)28.43K
Market Cap
$7.26M
Enterprise Value$9.41M
Total Cash (Recent Filing)$824.00K
Total Debt (Recent Filing)$577.00K
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Nov 17, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding10,376,109
10 Day Avg. Volume23,384
30 Day Avg. Volume28,433
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue11.08
Enterprise Value/Gross Profit18.02
Enterprise Value/Ebitda-0.81
Forecast
1Y Price Target
$6.60Price Target Upside842.86% Upside
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Community SupportThere is growing support for NurOwn's approval, driven by media coverage and independent advocacy, including a Citizens' Petition.
Regulatory ApprovalThe P3b study in ALS has been cleared by FDA, and the company plans to conduct the study under the Special Protocol Assessment.
Therapeutic EfficacyReal-world data, like the 90% survival in the Expanded Access Program, warrants reconsideration by the FDA.
Bears Say
Financial ChallengesBrainStorm reported a net loss and will need to raise additional capital to move forward with the P3b study of NurOwn.
Funding RisksThe company needs to raise capital and the delisting along with the sharp decline in the share price increases the risk of an incrementally dilutive financing.
Stock PerformanceShares of BrainStorm Cell Therapeutics were downgraded to Hold due to capital needs and recent delisting.
Brainstorm Cell Therapeutics News
BCLI FAQ
What was Brainstorm Cell Therapeutics’s price range in the past 12 months?
Brainstorm Cell Therapeutics lowest stock price was $0.52 and its highest was $3.78 in the past 12 months.
What is Brainstorm Cell Therapeutics’s market cap?
Brainstorm Cell Therapeutics’s market cap is $7.26M.
When is Brainstorm Cell Therapeutics’s upcoming earnings report date?
Brainstorm Cell Therapeutics’s upcoming earnings report date is Nov 17, 2025 which is in 52 days.
How were Brainstorm Cell Therapeutics’s earnings last quarter?
Brainstorm Cell Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.37 by $0.03.
Is Brainstorm Cell Therapeutics overvalued?
According to Wall Street analysts Brainstorm Cell Therapeutics’s price is currently Undervalued.
Does Brainstorm Cell Therapeutics pay dividends?
Brainstorm Cell Therapeutics does not currently pay dividends.
What is Brainstorm Cell Therapeutics’s EPS estimate?
Brainstorm Cell Therapeutics’s EPS estimate is -0.37.
How many shares outstanding does Brainstorm Cell Therapeutics have?
Brainstorm Cell Therapeutics has 10,376,109 shares outstanding.
What happened to Brainstorm Cell Therapeutics’s price movement after its last earnings report?
Brainstorm Cell Therapeutics reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.37. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Brainstorm Cell Therapeutics?
Currently, no hedge funds are holding shares in BCLI
Company Description
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics (BCLI) is a biotechnology company focused on the development of innovative cellular therapies for the treatment of neurodegenerative diseases. Operating primarily in the biotechnology sector, the company's core product is NurOwn, an autologous cellular therapy that utilizes mesenchymal stem cells to deliver neurotrophic factors directly to the site of damage in the nervous system. Brainstorm is committed to providing transformative solutions that improve patient outcomes and address unmet medical needs in conditions such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
BCLI Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements towards clinical trials and strong community support, but these were overshadowed by financial challenges, NASDAQ delisting, and funding uncertainties. The sentiment is balanced between optimism for future trials and concern over current financial hurdles.View all BCLI earnings summariesBCLI Stock 12 Month Forecast
Average Price Target
$6.60
▲(842.86% Upside)
Technical Analysis
Ownership Overview
7.64% Insiders
0.80% Mutual Funds
3.74% Other Institutional Investors
87.82% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---